Form 4: Viking Therapeutics Director Exercises Stock Options, Disposes of Shares
SEC Form 4
Matthew W. Foehr, a director at Viking Therapeutics, exercised stock options and disposed of 20,786 shares of common stock on April 11, 2025.
Summary
- On April 11, 2025, Matthew W. Foehr, a director of Viking Therapeutics, Inc., executed a transaction involving the company's stock.
- Foehr exercised stock options to acquire 20,786 shares of common stock at a price of $8 per share.
- Simultaneously, Foehr disposed of 20,786 shares of common stock.
- Following the reported transaction, Foehr directly owns 132,036 shares of Viking Therapeutics.
Sentiment
Score: 5
Explanation: This is a neutral regulatory filing detailing a routine transaction. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential sentiment.
Stakeholder Impact
- The transaction may have a minor impact on shareholders due to the change in ownership, but it is unlikely to be significant.
Key Dates
| Date | Description |
|---|---|
| 05/26/2016 | Date the Stock Option was exercisable |
| 04/28/2025 | Expiration date of the Stock Option |
| 04/11/2025 | Date of transaction: stock option exercise and disposal of shares |
| 04/14/2025 | Date of signature for the Form 4 filing |
Keywords
Viking Therapeutics, VKTX, Director, Stock Options, Form 4, Beneficial Ownership, Matthew W. Foehr, Securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.